Reduced CD34+ Stem Cells Predicts CV Outcome in T2DM

Share this content:
Reduced CD34<sup>&#43;</sup> Stem Cells Predicts CV Outcome in T2DM
Reduced CD34+ Stem Cells Predicts CV Outcome in T2DM

THURSDAY, Nov. 10, 2016 (HealthDay News) -- Reduced baseline levels of circulating CD34+ stem cells predict adverse cardiovascular outcomes for patients with type 2 diabetes, according to a study published online Nov. 4 in Diabetes Care.

Gian Paolo Fadini, M.D., Ph.D., from the University of Padova in Italy, and colleagues monitored a cohort of 187 patients with type 2 diabetes for a median of 6.1 years. Six stem/progenitor cell phenotypes were measured in peripheral blood at baseline, based on expression of CD34, CD133, and KDR.

The researchers found that the primary outcome of time to a first cardiovascular event plus hospitalization for cardiovascular causes occurred in 48 patients (4.5/100 patient-years). Significantly lower CD34+ and CD34+CD133+ cells were seen in patients with versus those without incident cardiovascular events. The rates of cardiovascular events were higher in patients with below median levels of CD34+ and CD34+CD133+. Reduced CD34+ and CD34+CD133+ cell count independently predicted future events in hazard regression analyses (hazard ratios, 2.21 and 2.98, respectively). C statistics, continuous net reclassification improvement, and/or integrated discrimination index were improved with addition of the CD34+ cell count to the reference model or the U.K. Prospective Diabetes Study risk engine.

"In patients with type 2 diabetes, a reduced baseline level of circulating CD34+ stem cells predicts adverse cardiovascular outcomes up to six years later and improves risk stratification," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Keytruda for All Cancers With Genetic Biomarker

FDA Approves Keytruda for All Cancers With Genetic ...

First medication sanctioned for any cancer, regardless of origin

Regular Chocolate Consumption May Lower Risk of A-Fib

Regular Chocolate Consumption May Lower Risk of A-Fib

13-year study finds lower odds for atrial fibrillation in people eating moderate amounts

Doctors Urged to Check Patient Drug History Before Opioid Rx

Doctors Urged to Check Patient Drug History Before ...

Opioid abuse down when physicians are legally obligated to check patient's drug history

is free, fast, and customized just for you!

Already a member?

Sign In Now »